Cargando…

Treat-to-Target in Atopic Dermatitis: An International Consensus on a Set of Core Decision Points for Systemic Therapies

Currently no treat-to-target framework to guide systemic treatment in adults with moderate-to-severe atopic dermatitis exists. We sought to reach international consensus through an eDelphi process on a core set of recommendations for such an approach. Recommendations were developed by an internation...

Descripción completa

Detalles Bibliográficos
Autores principales: DE BRUIN-WELLER, Marjolein, BIEDERMANN, Tilo, BISSONNETTE, Robert, DELEURAN, Mette, FOLEY, Peter, GIROLOMONI, Giampiero, HERCOGOVÁ, Jana, HONG, Chih-Ho, KATOH, Norito, PINK, Andrew E., RICHARD, Marie-Aleth, SHUMACK, Stephen, SILVESTRE, Juan F., WEIDINGER, Stephan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Society for Publication of Acta Dermato-Venereologica 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9366686/
https://www.ncbi.nlm.nih.gov/pubmed/33491094
http://dx.doi.org/10.2340/00015555-3751
Descripción
Sumario:Currently no treat-to-target framework to guide systemic treatment in adults with moderate-to-severe atopic dermatitis exists. We sought to reach international consensus through an eDelphi process on a core set of recommendations for such an approach. Recommendations were developed by an international Steerng Committee, spanning 3 areas (Guiding Principles, Decision Making, and Outcome Thresholds) and 2 specific time-points; an initial acceptable target at 3 months and an optimal target at 6 months, each based on improvements in patient global assessment plus at least one specific outcome domain. These treat-to-target-orientated recommendations were evaluated by an extended international panel of physicians, nurses and patients. Proposed recommendations were rated using a 9-point Likert scale; for each recommendation, consensus agreement was reached if ≥ 75% of all respondents rated agreement as ≥ 7. Consensus on 16 core recommendations was reached over 2 eDelphi rounds. These provide a framework for shared decision-making on systemic treatment continuation, modification, or discontinuation.